drugset / Trial / NCT01830660
A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Hetrombopag Olamine made by Jiangsu Hengrui Medicine co Ltd. has shown an effect of increasing platelet count in animal and human. This study is designed in dose escalation fashion to evaluate safety, pharmacokinetics and efficacy of Hetrombopag Olamine.
Timeline
- Start
- 2012-04
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hetrombopag | Small molecule | 2.5 mg | Oral |
| Subject | Hetrombopag | Small molecule | 5 mg | Oral |
| Subject | Hetrombopag | Small molecule | 10 mg | Oral |
| Subject | Hetrombopag | Small molecule | 20 mg | Oral |
| Subject | Hetrombopag | Small molecule | 30 mg | Oral |
| Subject | Hetrombopag | Small molecule | 40 mg | Oral |
Indications
No indication recorded.